Glucotrack Subsidiary Advances Single-Injection Administration Strategy
Lokahi Therapeutics completed a nonclinical study supporting a shift from 15 injections to a single subcutaneous injection, with regulatory discussions encouraging an accelerated clinical timeline for 2026.
View filing at SEC.gov →